aTyr Pharma, Inc.
ATYR
$3.99
$0.4412.39%
| Weiss Ratings | ATYR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ATYR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ATYR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.84 | |||
| Price History | ATYR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 31.68% | |||
| 30-Day Total Return | 9.92% | |||
| 60-Day Total Return | 32.12% | |||
| 90-Day Total Return | 27.48% | |||
| Year to Date Total Return | 2.05% | |||
| 1-Year Total Return | 144.79% | |||
| 2-Year Total Return | 104.62% | |||
| 3-Year Total Return | -16.00% | |||
| 5-Year Total Return | 48.88% | |||
| 52-Week High % Change | -23.82% | |||
| 52-Week Low % Change | 150.00% | |||
| Price | ATYR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $4.66 | |||
| 52-Week Low Price | $1.42 | |||
| 52-Week Low Price (Date) | Jun 21, 2024 | |||
| 52-Week High Price (Date) | Feb 21, 2025 | |||
| Valuation | ATYR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 298.00M | |||
| Enterprise Value | 245.39M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.94 | |||
| Earnings Per Share Growth | -3.19% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1,145.16 | |||
| Price/Book (Q) | 4.12 | |||
| Enterprise Value/Revenue (TTM) | 1,044.22 | |||
| Price | $3.99 | |||
| Enterprise Value/EBITDA (TTM) | -3.64 | |||
| Enterprise Value/EBIT | -3.61 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | ATYR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 75.80M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ATYR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 731 8389 | |||
| Address | 10240 Sorrento Valley Road San Diego, CA 92121 | |||
| Website | www.atyrpharma.com | |||
| Country | United States | |||
| Year Founded | 2005 | |||
| Profitability | ATYR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -28,958.72% | |||
| Profit Margin | -27,155.74% | |||
| Management Effectiveness | ATYR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -39.26% | |||
| Return on Equity | -- | |||
| Income Statement | ATYR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 235.00K | |||
| Total Revenue (TTM) | 235.00K | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | -54.66M | |||
| EBITDA (TTM) | -67.35M | |||
| EBIT (TTM) | -68.05M | |||
| Net Income (TTM) | -63.82M | |||
| Net Income Avl. to Common (TTM) | -63.82M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -52.19% | |||
| EPS Diluted (TTM) | -0.94 | |||
| EPS Diluted Growth (Q YOY) | -16.23% | |||
| Balance Sheet | ATYR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 65.99M | |||
| Cash Per Share (Q) | $0.87 | |||
| Total Current Assets (Q) | 76.32M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 65.14M | |||
| Current Ratio (Q) | 5.406 | |||
| Book Value Per Share (Q) | $0.86 | |||
| Total Assets (Q) | 91.62M | |||
| Total Current Liabilities (Q) | 14.12M | |||
| Total Debt (Q) | 13.57M | |||
| Total Liabilities (Q) | 26.48M | |||
| Total Common Equity (Q) | 65.33M | |||
| Cash Flow | ATYR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 41.14M | |||
| Cash from Financing (TTM) | 27.06M | |||
| Net Change in Cash (TTM) | 1.15M | |||
| Levered Free Cash Flow (TTM) | -41.67M | |||
| Cash from Operations (TTM) | -67.05M | |||
